Musaddiq Khan

Director, Clinical Program Operations Eli Lilly

Clinical Trial Design Agenda

Thursday, December 10th, 2020

12:30 PM PANEL DISCUSSION: VIRTUAL, DECENTRALISED AND HYBRID CLINICAL TRIALS IN LIGHT OF THE CURRENT PANDEMIC

  • How is the industry reacting to this shift in leveraging remote strategies?
  • How do we balance key factors such as patient centricity, data, regulation, compliance and cost, and should flexibility be the greatest priority?
  • What impact is this having on the regulators and how they operate?
  • Will remote trials affect data endpoints and to what extent?
  • What impact do virtual, decentralised and hybrid trials have on patients and how can we reduce potential burdens?
  • How is this influencing patient engagement strategies?